Sensus Healthcare (NASDAQ:SRTS) Director Acquires $96,656.16 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta purchased 27,304 shares of Sensus Healthcare stock in a transaction dated Monday, August 31st. The stock was bought at an average cost of $3.54 per share, with a total value of $96,656.16. Following the completion of the purchase, the director owned 294,784 shares in the company, valued at approximately $1,043,535.36. This trade represents a 10.21% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Eric Sachetta also recently made the following trade(s):

• On Friday, August 28th, Eric Sachetta bought 37,537 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.44 per share, with a total value of $129,127.28.
• On Thursday, August 27th, Eric Sachetta purchased 10,925 shares of Sensus Healthcare stock. The shares were purchased at an average cost of $3.18 per share, with a total value of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The stock was purchased at an average cost of $3.29 per share, for a total transaction of $31,939.32.
• On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Stock Down 2.4%

NASDAQ:SRTS opened at $3.25 on Thursday. The business’s 50-day moving average price is $3.08 and its 200 day moving average price is $3.49. The firm has a market cap of $53.49 million, a P/E ratio of -3.46 and a beta of 1.13. Sensus Healthcare, Inc. has a 52-week low of $2.66 and a 52-week high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $4.60 million.

Wall Street Analyst Weigh In

SRTS has been the topic of several research reports. Lake Street Capital dropped their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Finally, Weiss Ratings lowered Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds have recently made changes to their positions in SRTS. EP Wealth Advisors LLC purchased a new position in Sensus Healthcare during the 2nd quarter worth approximately $49,000. BlackRock Inc. purchased a new stake in shares of Sensus Healthcare in the second quarter valued at $252,000. Bank of New York Mellon Corp acquired a new stake in shares of Sensus Healthcare in the second quarter worth $303,000. North Star Investment Management Corp. purchased a new position in shares of Sensus Healthcare during the first quarter valued at $500,000. Finally, XTX Topco Ltd purchased a new position in shares of Sensus Healthcare during the fourth quarter valued at $77,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.